Fusion is utilizing the advantages of alpha medical isotopes to develop targeted alpha therapeutics. We use targeting molecules, such as antibodies, armed with these potent alpha emitting medical isotopes to precisely and effectively induce cancer cell death. Since alpha particles travel only a short distance, they localize the radiation to the tumor.
The Science Behind
Technology Platform Overview
We believe that our Fast-Clear™ Technology Platform promotes a wider therapeutic window with a potentially safer and more effective therapy than currently available options.
Fusion’s proprietary Fast-Clear™ Technology Platform promotes the rapid excretion of medical isotopes that are not specifically bound to cancer cells. The Fast-Clear™ Linker (the “connector” between a molecule and a medical isotope) is engineered to clear more medical isotope at a faster rate, compared to commercial technologies, with the aim of expanding the therapeutic window. Fusion has a library of proprietary linkers that can optimize the excretion route and kinetics for different targeting molecules.
Given the power and versatility of the Fast-Clear™ Technology Platform, Fusion is applying this technology to a range of molecules and molecule classes (antibodies, small molecules, and others).
Contact us to learn more about Fusion’s Fast-Clear™ Technology and partnering opportunities